LBA59 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8)
| Autor: | Cho, B.C., Obermannova, R., Orlov, S.V., Batra, U., Geater, S.L., McKeage, M., Yang, C.-T., Postmus, P.E., de Castro, G., Kim, S.-W., De Marchi, P., Kanakasetty, G.B., Sriuranpong, V., Voon, P.J., Lau, Y.Y., Kiertsman, F., Passos, V.Q., Chen, Z., Dziadziuszko, R. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|